{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:15:17Z","timestamp":1777349717284,"version":"3.51.4"},"reference-count":56,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2018,1,13]]},"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>It is well recognised that over the past three to four decades the incidence of asymptomatic primary hyperparathyroidism has increased significantly. However, more recently this pattern has further evolved into a presentation with normocalcaemia and raised parathyroid hormone (PTH) level without the presence of a recognised stimulus for its rise, in the form of vitamin D deficiency or renal impairment. A diagnostic label of normocalcaemic hyperparathyroidism (NPHPT) has been given to this phenotype and in most such individuals, the initial PTH measurement is driven by the presence of metabolic bone disease. The reported prevalence, degree of end-organ involvement and the rate of progression vary considerably and are related to patients studied and the biochemical cut-offs used in its definition. A majority of patients are diagnosed during assessment of metabolic bone disease of varying degrees. Once the diagnosis is confirmed by excluding confounding factors, the patient should undergo full assessment of end-organ involvement, which is the main determinant of further therapeutic decisions. Surgery, with prior localisation, is considered in patients with significant end-organ involvement in keeping with the guidance for hypercalcaemic patients. If a patient does not meet these criteria, annual clinical and biochemical surveillance is recommended to identify progression to hypercalcaemia or worsening end-organ involvement. It is less clear if patients identified during \u2018routine\u2019 requests for evaluation of unrelated symptoms require similar close monitoring. In conclusion, in this review on NPHPT we focus on its definition, planning of further investigations, selection of patients for intervention and devising an appropriate follow-up strategy.<\/jats:p>","DOI":"10.1136\/jclinpath-2017-204455","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T12:15:18Z","timestamp":1517660118000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Normocalcaemic primary hyperparathyroidism: a pragmatic approach"],"prefix":"10.1136","volume":"71","author":[{"given":"Feaz","family":"Babwah","sequence":"first","affiliation":[{"name":"Wolverhampton Endocrine and Diabetes Unit, New Cross Hospital, Wolverhampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harit N","family":"Buch","sequence":"additional","affiliation":[{"name":"Wolverhampton Endocrine and Diabetes Unit, New Cross Hospital, Wolverhampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,3]]},"reference":[{"key":"2025121400063794000_71.4.291.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4022"},{"key":"2025121400063794000_71.4.291.2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1215"},{"key":"2025121400063794000_71.4.291.3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(69)90222-8"},{"key":"2025121400063794000_71.4.291.4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1763"},{"key":"2025121400063794000_71.4.291.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2012.12.001"},{"key":"2025121400063794000_71.4.291.6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2802"},{"key":"2025121400063794000_71.4.291.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1414"},{"key":"2025121400063794000_71.4.291.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031014"},{"key":"2025121400063794000_71.4.291.9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-6-1294"},{"key":"2025121400063794000_71.4.291.10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021404"},{"key":"2025121400063794000_71.4.291.11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4158\/EP15704.OR","article-title":"Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat?","volume":"22","author":"\u0160iprov\u00e1","year":"2016","journal-title":"Endocr Pract"},{"key":"2025121400063794000_71.4.291.12","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050910"},{"key":"2025121400063794000_71.4.291.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.037"},{"key":"2025121400063794000_71.4.291.14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: A long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol"},{"key":"2025121400063794000_71.4.291.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(97)90357-3"},{"key":"2025121400063794000_71.4.291.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-002-6621-0"},{"key":"2025121400063794000_71.4.291.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1300"},{"key":"2025121400063794000_71.4.291.18","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9694-z"},{"key":"2025121400063794000_71.4.291.19","unstructured":"Berger C , Langsetmo L , Hanley D , et al . Relative prevalence of normocalcemic and hypercalcemic hyperparathryoidism in a community-dwelling cohort. 33rd annual meeting of the American society of bone and mineral research. San Diego, CA, 2011. Abstract 0173."},{"key":"2025121400063794000_71.4.291.20","first-page":"456.e1","article-title":"[Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up]","volume":"60","author":"Mart\u00ednez D\u00edaz-Guerra","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"2025121400063794000_71.4.291.21","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302011000500003"},{"key":"2025121400063794000_71.4.291.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.04.002"},{"key":"2025121400063794000_71.4.291.23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007121327"},{"key":"2025121400063794000_71.4.291.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-012-1438-y"},{"key":"2025121400063794000_71.4.291.25","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2015-204669"},{"key":"2025121400063794000_71.4.291.26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/cen.13056","article-title":"Elevated PTH with normal serum calcium level: a structured approach","volume":"84","author":"Crowley","year":"2016","journal-title":"Clin Endocrinol"},{"key":"2025121400063794000_71.4.291.27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1515\/cclm-2014-0150","article-title":"LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations","volume":"52","author":"Couchman","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2025121400063794000_71.4.291.28","unstructured":"Marshall W . Association for clinical biochemistry and laboratory medicine. 2012 http:\/\/www.acb.org.uk\/whatwedo\/science\/AMALC.aspx (accessed 1 Aug 2017)."},{"key":"2025121400063794000_71.4.291.29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021370"},{"key":"2025121400063794000_71.4.291.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-005-0647-y"},{"key":"2025121400063794000_71.4.291.31","doi-asserted-by":"crossref","unstructured":"Julian M-T , Olaizola I , Diaz-Soto G , et al . Diaz-Soto G , ed. Normocalcemic primary hyperparathyroidism, hyperparathyroidism, 2012. ISBN: 978-953-51-0478-0. http:\/\/www.intechopen.com\/books\/hyperparathyroidism\/normocalcemic-primary-hyperparathyroidism","DOI":"10.5772\/39203"},{"key":"2025121400063794000_71.4.291.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60507-9"},{"key":"2025121400063794000_71.4.291.33","doi-asserted-by":"publisher","DOI":"10.4158\/EP10389.OR"},{"key":"2025121400063794000_71.4.291.34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107156"},{"key":"2025121400063794000_71.4.291.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2015.03.005"},{"key":"2025121400063794000_71.4.291.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/128352","article-title":"Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More stone than bone?","volume":"2012","author":"Amaral","year":"2012","journal-title":"J Osteoporos"},{"key":"2025121400063794000_71.4.291.37","unstructured":"Kanis JA . FRAX \u00ae Fracture Risk Assessment Tool, 2016. https:\/\/www.sheffield.ac.uk\/FRAX\/index.aspx (accessed 1 Nov 2017)."},{"key":"2025121400063794000_71.4.291.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9454-0"},{"key":"2025121400063794000_71.4.291.39","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2102"},{"key":"2025121400063794000_71.4.291.40","doi-asserted-by":"publisher","DOI":"10.4081\/aiua.2015.1.66"},{"key":"2025121400063794000_71.4.291.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00270-2"},{"key":"2025121400063794000_71.4.291.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03958.x"},{"key":"2025121400063794000_71.4.291.43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-8587(13)70083-4","article-title":"Subclinical and asymptomatic parathyroid disease: implications of emerging data","volume":"1","author":"Macfarlane","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121400063794000_71.4.291.44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1507\/endocrj.EJ15-0392","article-title":"Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients","volume":"63","author":"Yener Ozturk","year":"2016","journal-title":"Endocr J"},{"key":"2025121400063794000_71.4.291.45","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9627-x"},{"key":"2025121400063794000_71.4.291.46","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4432"},{"key":"2025121400063794000_71.4.291.47","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1413"},{"key":"2025121400063794000_71.4.291.48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2000"},{"key":"2025121400063794000_71.4.291.49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.14310\/horm.2002.1370","article-title":"Normocalcemic primary hyperparathyroidism: A newly emerging disease needing therapeutic intervention","volume":"11","author":"D\u00edaz-Soto","year":"2012","journal-title":"Hormones"},{"key":"2025121400063794000_71.4.291.50","first-page":"475","article-title":"Parathyroid adenomas and glands in normocalcemic hyperparathyroidism - a light microscopic study","volume":"83","author":"Grimelius","year":"1976","journal-title":"Am J Pathol"},{"key":"2025121400063794000_71.4.291.51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2499"},{"key":"2025121400063794000_71.4.291.52","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1518"},{"key":"2025121400063794000_71.4.291.53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2384"},{"key":"2025121400063794000_71.4.291.54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1472"},{"key":"2025121400063794000_71.4.291.55","unstructured":"National Institute for Biological Standards and Control, NIBSC. WHO International standard parathyroid hormone 1-84, human recombinant, NIBSC code 95\/646, version 9.0. 2010. http:\/\/www.nibsc.org\/documents\/ifu\/95-646.pdf (accessed 1 Aug 2017)."},{"issue":"Suppl","key":"2025121400063794000_71.4.291.56","article-title":"Improving the comparability of parathyroid hormone measurements \u2013 a report from the IFCC working group for PTH","volume":"37","author":"Sturgeon","year":"2013","journal-title":"Biochimica Clinica"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2017-204455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:06:46Z","timestamp":1765699606000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2017-204455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,3]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,3,20]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/jclinpath-2017-204455"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2017-204455","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,3]]}}}